Agilent Technologies and Rosetta Inpharmatics License Rosetta Resolver Data Analysis System to the Harvard Center for Genomics Research
Center to Serve the Gene Expression Data Analysis Needs of Life Sciences
Research Groups within the University.
PALO ALTO, Calif., and KIRKLAND, Wash., July 24 /PRNewswire/ -- Agilent
Technologies Inc (NYSE: A) and Rosetta Inpharmatics Inc. today announced that
the Center for Genomics Research at Harvard University has licensed the
Rosetta Resolver(TM) Expression Data Analysis System for life science work.
The Rosetta Resolver package is an enterprise-level bioinformatics system for
gene expression research developed by Rosetta Inpharmatics and exclusively
distributed by Agilent Technologies. The Rosetta Resolver System will be used
by the Center to analyze data from a variety of commercial and internally
developed DNA chip technologies, including Affymetrix(R) GeneChip arrays.
Formed a year ago, the Harvard Center for Genomics Research integrates
scientific and engineering disciplines in order to develop new genomics tools
and to apply them to biological problems. The Center provides access to
genomics technologies to a broad range of research groups from the various
schools and hospitals affiliated with Harvard.
"The demands on the Genomics Center for gene microarray expression
analysis are increasing dramatically and we needed an analysis system with a
suite of bioinformatics tools that is both customizable and available now,"
said Dr. George Busby, director of administration of the Center for Genomics
Research. "Given the vast amounts of data generated by our microarray
experiments, we wanted an enterprise-level tool that is capable of analyzing
and storing massive quantities of data from multiple microarray platforms."
"We are pleased to have one of the world's most prestigious academic
institutions licensing the Rosetta Resolver System," said Bill Buffington,
vice president and general manager of Agilent's Bioscience Products Group.
"We believe that Rosetta provides the industry's most powerful bioinformatics
platform, and selection of the Rosetta Resolver package by Harvard's Center
for Genomics Research for their multi-department gene expression program
serves to highlight that leadership. Agilent is pleased to be offering the
Rosetta Resolver System as part of a rapidly expanding portfolio of products
for our growing base of life sciences customers."
About Rosetta Inpharmatics
Rosetta Inpharmatics offers solutions to the emerging field of
informational genomics. By combining the power of informatics and genomics,
Rosetta has created a proprietary platform that accelerates and enhances the
drug discovery process for pharmaceutical and biotechnology companies, and
improves agricultural products. Rosetta Inpharmatics' approach converts the
rapidly growing amount of gene expression data, or information about a gene's
activity, into organized, statistically driven, information-based results.
Rosetta Inpharmatics provides a proprietary gene expression profiling
platform, consisting of hardware and software products, that uses gene
expression profiles to provide seamless solutions for efficient,
cost-effective and powerful discovery programs. Rosetta Inpharmatics'
technology builds a critical mass of coherent gene expression data collected
from DNA microarrays, which are comprised of DNA fragments attached to glass
slides in a grid-like formation. This platform provides comprehensive,
simultaneous descriptions of a compound's effect on all relevant targets
within a cell.
Information about Rosetta Inpharmatics can be found on the Web at
rii.com.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a diversified technology company,
resulting from Hewlett-Packard Company's plan to strategically realign itself
into two fully independent companies. With approximately 43,000 employees
serving customers in more than 120 countries, Agilent Technologies is a global
leader in designing and manufacturing test, measurement and monitoring
instruments, systems and solutions, and semiconductor and optical components.
The company serves markets that include communications, electronics, life
sciences and healthcare. In fiscal year 1999, the businesses comprising
Agilent, then a subsidiary of HP, had net revenue of more than $8.3 billion.
Information about Agilent Technologies can be found on the Web at
agilent.com.
Rosetta Inpharmatics' Forward-Looking Statements
Except for the historical information presented, certain matters discussed
in this press release are forward-looking statements that are subject to
certain risks and uncertainties that could cause actual results to differ
materially from any future results, performance or achievements expressed or
implied by such statements.
Rosetta Resolver is a U.S. trademark of Rosetta Inpharmatics Inc.
Affymetrix is a U.S. registered trademark used by Affymetrix Inc.
Douglas Forsyth, Agilent
650-857-5603
doug-forsyth@agilent.com
Rosetta Inpharmatics
Mary Drummond, Media Relations Greg Sessler, Investor Relations
425-823-7369 425-636-6306
mdrummond@rii.com gsessler@rii.com
Noonan/Russo Communications (for Rosetta)
Kesinee Yip, Ana Kapor,
415-677-4455, ext. 244 415-677-4455, ext. 207
k.yip@noonanrusso.com a.kapor@noonanrusso.com
SOURCE Rosetta Inpharmetics Inc. and Agilent Technologies Inc
CO: Rosetta Inpharmetics Inc.; Agilent Technologies Inc
ST: California, Massachusetts
IN: MTC BIO HEA
SU: LIC
07/24/2000 09:01 EDT prnewswire.com |
